Breaking Down SG&A Expenses: United Therapeutics Corporation vs Ligand Pharmaceuticals Incorporated

SG&A Expenses: United Therapeutics vs. Ligand Pharmaceuticals

__timestampLigand Pharmaceuticals IncorporatedUnited Therapeutics Corporation
Wednesday, January 1, 201422570000381287000
Thursday, January 1, 201524378000452612000
Friday, January 1, 201626621000316800000
Sunday, January 1, 201728653000330100000
Monday, January 1, 201837734000265800000
Tuesday, January 1, 201941884000336200000
Wednesday, January 1, 202064435000423900000
Friday, January 1, 202157483000467000000
Saturday, January 1, 202270062000487000000
Sunday, January 1, 202352790000477100000
Loading chart...

Data in motion

A Comparative Analysis of SG&A Expenses: United Therapeutics vs. Ligand Pharmaceuticals

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of United Therapeutics Corporation and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Over this period, United Therapeutics consistently outspent Ligand Pharmaceuticals, with SG&A expenses peaking at approximately $487 million in 2022, a staggering 600% more than Ligand's highest expenditure of around $70 million in the same year. Notably, Ligand's expenses saw a significant increase of over 200% from 2014 to 2022, reflecting strategic investments in growth and operations. Meanwhile, United Therapeutics maintained a steady upward trend, underscoring its robust market position. This financial insight not only highlights the contrasting strategies of these two companies but also offers a glimpse into their operational priorities over the past decade.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025